Vol 7, No 1 (2021)
Review paper
Published online: 2021-05-20
Mechanizm, działanie i skuteczność glikokortykosteroidów w polimialgii reumatycznej i olbrzymiokomórkowym zapaleniu tętnic –– czy te leki są zawsze skuteczne?
1
, 2, 2, 1
, 2, 2, 1
DOI: 10.5603/FR.2021.0006
Forum Reumatol 2021;7(1):27-34.
Abstract
W terapii polimialgii reumatycznej (PMR, polymialgia rheumatica) i olbrzymiokomórkowego zapalenia tętnic (GCA, giant cells arthritis) lekami pierwszego wyboru są glikokortykosteroidy (GKS). Powyższe choroby wymagają często wieloletniego leczenia, dlatego należy zwrócić szczególną uwagę na szerokie spektrum działań niepożądanych tych leków. Problemem, z którym można spotkać się w praktyce klinicznej, jest steroidooporność. W niniejszej publikacji zebrano najnowsze doniesienia naukowe dotyczących skuteczności terapii GKS w PMR współistniejącej (lub nie) z GCA.
Keywords: polimialgia reumatycznaolbrzymiokomórkowe zapalenie tętnicsteroidoterapia
References
- Fors C, Bergström U, Willim M, Pilman E, Turesson C. Validity of polymyalgia rheumatica diagnoses and classification criteria in primary health care. Rheumatol Adv Pract. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799851/ (23 styczenia 2021).
- Hunder GG. Classification/diagnostic criteria for GCA/PMR. Clin Exp Rheumatol. 2000; 18(4 Suppl 20): S4–S5.
- Cantini F, Niccoli L, Storri L, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum. 2004; 33(5): 294–301.
- Albrecht K, Huscher D, Buttgereit F, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int. 2018; 38(4): 569–577.
- Yin Y, Zhang Y, Wang D, et al. Differences in clinical manifestations and prognosis of Chinese giant cell arteritis patients with or without polymyalgia rheumatica. Ir J Med Sci. 2019; 188(2): 713–720.
- Kermani TA. Polymyalgia rheumatica. 2013; 381: 10.
- Raczkiewicz A. Starszy pacjent w standardach postępowania reumatologicznego. Forum Medycyny Rodzinnej. 2009; 5(3): 372–379.
- Pyszel A, Andrzejak R, Szuba A. Large-vessel giant cell arteritis. 2006; 12(1): 8.
- Adizie T, Dasgupta B. PMR and GCA: steroids or bust. International Journal of Clinical Practice. 2012; 66(6): 524–527.
- Kermani TA, Sreih AG, Cuthbertson D, et al. Vasculitis Clinical Research Consortium. Evaluation of damage in giant cell arteritis. Rheumatology (Oxford). 2018; 57(2): 322–328.
- Grzanka A, Misiołek M, Golusiński W, et al. [Nongenomic effects of glucocorticoids]. Pneumonol Alergol Pol. 2009; 77(4): 387–393.
- Becker DE. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013; 60(1): 25–31; quiz 32.
- Martinez-Taboada VM, Alvarez L, RuizSoto M, et al. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine. 2008; 44(2): 207–220.
- Spies CM, Bijlsma JWJ, Burmester GR, et al. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol. 2010; 10(3): 302–307.
- Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008; 4(10): 525–533.
- Schäcke H, Schottelius A, Döcke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A. 2004; 101(1): 227–232.
- Hübner S, Dejager L, Libert C, et al. The glucocorticoid receptor in inflammatory processes: transrepression is not enough. Biol Chem. 2015; 396(11): 1223–1231.
- Hayashi R, Wada H, Ito K, et al. Effects of glucocorticoids on gene transcription. Eur J Pharmacol. 2004; 500(1-3): 51–62.
- Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002; 67(6): 529–534.
- Song IH, Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol. 2006; 246(1-2): 142–146.
- Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol. 1999; 58(2): 363–368.
- Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc. 2004; 1(3): 255–263.
- Haller J, Mikics E, Makara GB. The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings. Front Neuroendocrinol. 2008; 29(2): 273–291.
- Malcher-Lopes R, Di S, Marcheselli VS, et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci. 2006; 26(24): 6643–6650.
- Mackiewicz S. Review paper
Glucocorticoid therapy – success or illusion. Reumatologia/Rheumatology. 2007; 45(4): 198–204. - Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15(4): 457–465.
- Cheah JTL, Robson JC, Black RJ, et al. The patient's perspective of the adverse effects of glucocorticoid use: A systematic review of quantitative and qualitative studies. From an OMERACT working group. Semin Arthritis Rheum. 2020; 50(5): 996–1005.
- Pereira R, Carvalho JF. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011; 78(1): 41–44.
- Sato A, Funder JW, Okubo M, et al. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens. 1995; 8(8): 823–828.
- Mori S, Koga Y. Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin Rheumatol. 2016; 35(5): 1367–1375.
- Lally L, Spiera R. Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice. Best Pract Res Clin Rheumatol. 2018; 32(6): 803–812.
- Liozon E, Dumonteil S, Parreau S, et al. Risk profiling for a refractory course of giant cell arteritis: The importance of age and body weight: "Risk profiling for GC resistance in GCA". Semin Arthritis Rheum. 2020; 50(6): 1252–1261.
- Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013; 9(12): 731–740.
- van der Geest KSM, Abdulahad WH, Rutgers A, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford). 2015; 54(8): 1397–1402.
- Owen CE, McMaster C, Liew DFL, et al. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica. Int J Rheum Dis. 2021; 24(1): 56–62.
- Jung JY, Lee E, Suh CH, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica. J Clin Lab Anal. 2019; 33(9): e23000.
- Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6): dju124.
- Kötter I, Henes JC, Wagner AD, et al. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol. 2012; 30(1 Suppl 70): S114–S129.
- Cimmino MA, Parodi M, Montecucco C, et al. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord. 2011; 12(1): 94.
- Ponte C, Rodrigues AF, O'Neill L, et al. Giant cell arteritis: Current treatment and management. World J Clin Cases. 2015; 3(6): 484–494.
- 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Annals of the Rheumatic Diseases. https://ard.bmj.com/content/74/10/1799?etoc (13 stycznia 2021).
- 2018 Update of the EULAR recommendations for the management of large vessel vasculitis | Annals of the Rheumatic Diseases. https://ard.bmj.com/content/79/1/19 (13 stycznia 2021).
- Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007; 56(8): 2789–2797.
- van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996; 55(4): 218–223.
- Camellino D, Soldano S, Cutolo M, et al. Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition. Rheumatol Int. 2018; 38(9): 1699–1704.
- Braun N, Fritz P, Rieth A, et al. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica. J Rheumatol. 2009; 36(10): 2269–2276.
